Abstract
Although effective in treating a range of childhood psychiatric conditions, selective serotonin reuptake inhibitors (SSRI) have been implicated in the induction of an “activation syndrome” (characterized by symptoms of irritability, restlessness, emotional labiality, etc.) that may represent an intermediary state change that fosters suicidality. SSRI-induced activation syndrome is well-accepted by many clinicians and thought to be relatively common, particularly in children and teens. However, gaps exist in empirical data on phenomenology and tools for early detection. With this in mind, we report on a recently funded National Institutes of Health grant to develop a measure of behavioral activation to be completed in a clinical setting. We discuss the development of this measure—the Treatment-Emergent Activation and Suicidality Assessment Profile (TE-ASAP)—as well as psychometric results from a sample of youth with internalizing disorders who were at varying stages of SSRI treatment. Overall, psychometric data were quite promising, with the TE-ASAP demonstrating excellent reliability (i.e., internal consistency, inter-rater, short-term test–retest stability) and strong validity properties. Through further evaluation of the TE-ASAP in the context of a controlled multimodal trial in youth with obsessive–compulsive disorder, we hope to augment understanding of activation syndrome and, in turn, mitigate risks through early detection of this potentially lifethreatening adverse effect.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Notes
It should be noted that the labels (e.g., Irritability) for the different dimensions of the scale are preliminary and intended only to help organize content during the construction of the instrument. These subscale names may be altered once we are satisfied that the domain range and factor structure has been established.
References
Achenbach, T. M., & Rescorla, L. A. (2001). Manual for the ASEBA school-age forms and profiles. Burlington, VT: University of Vermont, Research Center for Children, Youth, & Families.
Adler, M., & Ziglio, E. (1996). Gazing into the oracle: The Delphi method and its application to social policy and public health. London: Jessica Kingsley Publishers.
Aman, M. G., & Singh, N. N. (1986). Aberrant Behavior Checklist: Manual. East Aurora, NY: Slosson Educational Publications.
Bandelow, B. (2008). The medical treatment of obsessive-compulsive disorder and anxiety. CNS Spectrums, 13, 37–46.
Barbui, C., Esposito, E., & Cipriani, A. (2009). Selective serotonin reuptake inhibitors and risk of suicide: A systematic review of observational studies. Canadian Medical Association Journal, 180, 291–297.
Barnes, T. R. (1989). A rating scale for drug-induced akathisia. British Journal of Psychiatry, 154, 672–676.
Beasley, C. M., Dornseif, B. E., Bosomworth, J., Sayler, M., Rampey, A., & Heiligenstein, J. (1991). Fluoxetine and suicide: A meta-analysis of controlled trials of treatment for depression. British Medical Journal, 303, 685–692.
Bridge, J. A., Iyengar, S., Salary, C. B., Barbe, R. P., Birmaher, B., Pincus, H. A., et al. (2007). Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: A meta-analysis of randomized controlled trials. Journal of the American Medical Association, 297, 1683–1696.
Bussing, R., Fernandez, M., Harwood, M., Hou, W., Garvan, C. W., Eyberg, S. M., et al. (2008). Parent and teacher SNAP-IV ratings of attention deficit hyperactivity disorder symptoms. Assessment, 15, 317–328.
Cunningham-Owens, D. G. (1999). A guide to the extrapyramidal side effects of antipsychotic drugs. Cambridge, MA: Cambridge University Press.
Department of Health, United Kingdom. (2003). Committee on safety of medicines, expert group on safety of SSRIs, minutes, June 20, 2003. Retrieved November 30, 2005, from Medicines and Healthcare products Regulatory Agency Web site: http://www.mhra.gov.uk/home/groups/pl-p/documents/committeedocument/con003485.pdf.
Freeman, J. B., Choate-Summers, M. L., Garcia, A. M., Moore, P. S., Sapyta, J. J., Khanna, M. S., et al. (2009). The pediatric obsessive-compulsive disorder treatment study II: Rationale, design, and methods. Child and Adolescent Psychiatry Mental Health, 3, 4.
Gibbons, R., Brown, C. H., Hur, K., Marcus, S., Bhaumik, D. K., & Erkens, J. A. (2007). Early evidence on the effects of regulators’ suicidality warning on SSRI prescriptions and suicide in children and adolescents. American Journal of Psychiatry, 164, 1356–1363.
Goodman, W. K., Murphy, T. K., & Storch, E. A. (2007). Risk of adverse behavioral effects with pediatric use of antidepressants. Psychopharmacology, 191, 87–96.
Gracious, B. L., Youngstrom, E. A., Findling, R. L., & Calabrese, J. R. (2002). Discriminative validity of a parent version of the Young Mania Rating Scale. Journal of American Academy of Child and Adolescent Psychiatry, 41, 1350–1359.
Hammad, T. A. (2004). Results of the analysis of suicidality in pediatric trials of newer antidepressants. Retrieved September 6, 2005, from http://www.fda.gov/ohrms/dockets/ac/04/slides/2004-4065s1.htm.
Keane, E., Dick, R., Bechtold, D., & Manson, S. (1996). Predictive and concurrent validity of the Suicidal Ideation Questionnaire among American Indian adolescents. Journal of Abnormal Child Psychology, 24, 735–747.
Letizia, C., Kapik, B., & Flanders, W. D. (1996). Suicidal risk during controlled clinical investigations of fluvoxamine. Journal of Clinical Psychiatry, 57, 415–421.
MacGillivray, S., Arroll, B., Hatcher, S., Ogston, S., Reid, I., Sullivan, F., et al. (2003). Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: Systematic review and meta-analysis. British Medical Journal, 326, 1014.
March, J. S., Biederman, J., Wolkow, R., Safferman, A., Mardekian, J., Cook, E. H., et al. (1998). Sertraline in children and adolescents with obsessive-compulsive disorder: A multicenter randomized controlled trial. Journal of the American Medical Association, 280, 1752–1756.
March, J., Silva, S., Petrycki, S., Curry, J., Wells, K., Fairbank, J., et al. (2004). Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for adolescents with depression study (TADS) randomized controlled trial. Journal of the American Medical Association, 292, 807–820.
Murphy, T. K., Segarra, A., Storch, E. A., & Goodman, W. K. (2008). SSRIs-adverse events: How to monitor and manage. International Review of Psychiatry, 20, 203–208.
Pavuluri, M. N., O’Connor, M. M., Harral, E. M., Moss, M., & Sweeney, J. A. (2006). Impact of neurocognitive function on academic difficulties in pediatric bipolar disorder: A clinical translation. Biological Psychiatry, 60, 951–956.
POTS. (2004). Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: The pediatric OCD treatment study (POTS) randomized controlled trial. Journal of the American Medical Association, 292, 1969–1976.
Poznanski, E. O., & Mokros, H. B. (1996). Children’s Depression Rating Scale-Revised, Manual. Los Angeles: Western Psychological Services.
Reynolds, W. (1988). SIQ professional manual. Odessa, FL: Psychological Assessment Resources, Inc.
Riddle, M. A., Reeve, E. A., Yaryura-Tobias, J. A., Yang, H. M., Claghorn, J. L., Gaffney, G., et al. (2001). Fluvoxamine for children and adolescents with obsessive-compulsive disorder: A randomized, controlled, multicenter trial. Journal of American Academy of Child and Adolescent Psychiatry, 40, 222–229.
Swanson, J. M. (1992). School based assessment and interventions for ADD students. Irvine, CA: KC Publications.
Teicher, M. H., Glod, C., & Cole, J. O. (1990). Emergence of intense suicidal preoccupation during fluoxetine treatment. American Journal of Psychiatry, 147, 207–210.
Teicher, M. H., Glod, C., & Cole, J. O. (1993). Antidepressant drugs and the emergence of suicidal tendencies. Drug Safety, 8, 186–212.
Walkup, J. T., Albano, A. M., Piacentini, J., Birmaher, B., Compton, S. N., Sherrill, J., et al. (2008). Cognitive-behavioral therapy, sertraline and their combination for children and adolescents with anxiety disorders: Acute phase efficacy and safety. New England Journal of Medicine, 359, 2753–2766.
Author information
Authors and Affiliations
Corresponding author
Additional information
This paper was supported by grants from the National Institutes of Health to the second author (L40 MH081950-02) and third author (1R01MH078594-01).
Rights and permissions
About this article
Cite this article
Reid, J.M., Storch, E.A., Murphy, T.K. et al. Development and Psychometric Evaluation of the Treatment-Emergent Activation and Suicidality Assessment Profile. Child Youth Care Forum 39, 113–124 (2010). https://doi.org/10.1007/s10566-010-9095-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10566-010-9095-5